Depemokimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Hypereosinophilic Syndrome. According to Globaldata, it is involved in 11 clinical trials, of which 2 were completed, and 9 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Depemokimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Depemokimab is expected to reach an annual total of $535 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Depemokimab Overview
Depemokimab (GSK-3511294) is under development for the treatment of asthma, eosinophilic granulomatous polyangiitis, rhinosinusitis and hypereosinophilic syndrome. It is administered through subcutaneous route as a solution. The therapeutic candidate is a new biological entity (NBE). It is a long acting monoclonal antibody that acts by targeting interleukin-5.
See Also:
GSK Overview
GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
For a complete picture of Depemokimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.